Characterizing poliovirus transmission and evolution: Insights from modeling experiences with wild and vaccine-related polioviruses

Risk Analysis

Volumn 33, Issue 4, 2013, Pages 703-749

  Duintjer Tebbens, Radboud J ^a   Pallansch, Mark A ^b   Kalkowska, Dominika A ^a,c   Wassilak, Steven G F ^d   Cochi, Stephen L ^d   Thompson, Kimberly M ^a,e  

^a Kid Risk Inc   (United States)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^c DELFT UNIVERSITY OF TECHNOLOGY   (Netherlands)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Disease outbreaks; Dynamic modeling; Polio eradication

Indexed keywords

BROAD APPLICATION; DISEASE OUTBREAKS; EQUATION-BASED MODELS; HISTORICAL EXPERIENCE; LITERATURE REVIEWS; POLIO ERADICATION; SPATIALLY HOMOGENEOUS; TRANSMISSION MODEL;

DIFFERENTIAL EQUATIONS; DYNAMIC MODELS; MIXING; VIRUSES;

VACCINES;

ORAL POLIOMYELITIS VACCINE;

DECISION MAKING; DISEASE TRANSMISSION; ECONOMIC ANALYSIS; ENDEMISM; HEALTH POLICY; HETEROGENEITY; IMMUNITY; LITERATURE REVIEW; NUMERICAL MODEL; POLIOMYELITIS; VACCINATION; VACCINE; VIRUS;

ARTICLE; CALIBRATION; DISEASE TRANSMISSION; EVOLUTION; GENETICS; HUMAN; IMMUNOLOGY; POLIOMYELITIS; POLIOMYELITIS VIRUS; THEORETICAL MODEL;

BIOLOGICAL EVOLUTION; CALIBRATION; HUMANS; MODELS, THEORETICAL; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINE, ORAL;

ALBANIA; NETHERLANDS; TAJIKISTAN;

POLIOVIRUS;

EID: 84875943515     PISSN: 02724332     EISSN: 15396924     Source Type: Journal    
DOI: 10.1111/risa.12044     Document Type: Article

References (128)

1. World Health Assembly. Global Eradication of Poliomyelitis by the Year 2000 (Resolution 41.28). Geneva: World Health Organization, 1988. Available at: http://www.who.int/csr/ihr/polioresolution4128en.pdf, accessed June 12, 2012.
2. World Health Organization. Transmission of wild poliovirus type 2 - apparent global interruption. Weekly Epidemiological Record, 2001; 76:95-97.
3. Centers for Disease Control and Prevention. Outbreaks following wild poliovirus importations-Europe, Africa, and Asia, January 2009-September 2010. Morbidity and Mortality Weekly Report, 2010; 59(43):1393-1399.
4. Centers for Disease Control and Prevention. Update on vaccine-derived polioviruses-worldwide, July 2009-March 2011. MMWR Morb Mortal Wkly Rep., 2011; 60(25):846-850.
5. Thompson KM, Pallansch MA, Duintjer Tebbens RJ, Wassilak SGF, Cochi SL. Modeling population immunity to support efforts to end the transmission of live polioviruses. Risk Analysis, 2013; 33(4):647-663.
6. Thompson KM, Pallansch MA, Duintjer Tebbens RJ, Wassilak SG, Kim J-H, Cochi SL. Pre-eradication vaccine policy options for poliovirus infection and disease control. Risk Analysis, 2013; 33(4):516-543.
7. Thompson KM, Duintjer Tebbens RJ. Current polio global eradication and control policy options: Perspectives from modeling and prerequisites for OPV cessation. Expert Reviews of Vaccines, 2012; 11(4):449-459.
8. Sangrujee N, Duintjer Tebbens RJ, Cáceres VM, Thompson KM. Policy decision options during the first 5 years following certification of polio eradication. Medscape General Medicine, 2003; 5(4):35.
9. Thompson KM, Duintjer Tebbens RJ. Retrospective cost-effectiveness analyses for polio vaccination in the United States. Risk Analysis, 2006; 26(6):1423-1440.
10. Thompson KM, Duintjer Tebbens RJ. Eradication versus control for poliomyelitis: An economic analysis. Lancet, 2007; 369(9570):1363-1371.
11. Thompson KM, Duintjer Tebbens RJ, Pallansch MA, Kew OM, Sutter RW, Aylward RB, Watkins M, Gary HE, Jr., Alexander JP, Jr., Jafari H, Cochi SL. The risks, costs, and benefits of possible future global policies for managing polioviruses. American Journal of Public Health, 2008; 98(7):1322-1330.
12. Thompson KM, Duintjer Tebbens RJ. Using system dynamics to develop policies that matter: Global management of poliomyelitis and beyond. System Dynamics Review, 2008; 24(4):433-449.
13. Duintjer Tebbens RJ, Pallansch MA, Kew OM, Cáceres VM, Sutter RW, Thompson KM. A dynamic model of poliomyelitis outbreaks: Learning from the past to help inform the future. American Journal of Epidemiology, 2005; 162(4):358-372.
14. Duintjer Tebbens RJ, Pallansch MA, Kew OM, Sutter RW, Aylward RB, Watkins M, Gary HE, Jr., Alexander JP, Jr., Jafari H, Cochi SL, Thompson KM. Uncertainty and sensitivity analyses of a decision analytic model for post-eradication polio risk management. Risk Analysis, 2008; 28(4):855-876.
15. Thompson KM, Duintjer Tebbens RJ, Pallansch MA. Evaluation of response scenarios to potential polio outbreaks using mathematical models. Risk Analysis, 2006; 26(6):1541-1556.
16. Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SGF, Linkins J, Sutter RW, Aylward RB, Thompson KM. Economic analysis of the Global Polio Eradication Initiative. Vaccine, 2011; 29(2):334-343.
17. Duintjer Tebbens RJ, Pallansch MA, Kim J-H, Burns CC, Kew OM, Oberste MS, Diop OM, Wassilak SGF, Cochi SL, Thompson KM. Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs). Risk Analysis, 2013; 33(4):680-702.
18. Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, Modlin JF, Patriarca PA, Sutter RW, Wright PF, Wassilak SGF, Cochi SL, Kim J-H, Thompson KM. Expert review on poliovirus immunity and transmission. Risk Analysis, 2013; 33(4):544-605.
19. Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, Modlin JF, Patriarca PA, Sutter RW, Wright PF, Wassilak SGF, Cochi SL, Kim J-H, Thompson KM. Review and assessment of poliovirus immunity and transmission: Synthesis of knowledge gaps and identification of research needs. Risk Analysis, 2013; 33(4):606-646.
20. Sutter RW, Kew OM, Cochi SL. Poliovirus vaccine-Live. Pp. 631-686 in Plotkin SA, Orenstein WA, Offit PA (eds). Vaccines. 5th ed. Philadelphia: Saunders Elsevier, 2008.
21. Melnick JL. Poliovirus and other enteroviruses. Pp. 583-663 in Evans AS, Kaslow RA (eds). Viral Infections of Humans: Epidemiology and Control. 4th ed. New York: Plenum Medical, 1997.
22. Minor PD. The molecular biology of poliovaccines. Journal of General Virology, 1992; 73(pt. 12):3065-3077.
23. Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annual Review of Microbiology, 2005; 59:587-635.
24. Chumakov K, Ehrenfeld E, Wimmer E, Agol VI. Vaccination against polio should not be stopped. Nature Reviews Microbiology, 2007; 5(12):952-958.
25. Nathanson N, Kew OM. From emergence to eradication: The epidemiology of poliomyelitis deconstructed. American Journal of Epidemiology, 2010; 172(11):1213-1229.
26. Eichner M, Dietz K. Eradication of poliomyelitis: When can one be sure that polio virus transmission has been terminated? American Journal of Epidemiology, 1996; 143(8):816-822.
27. Eichner M, Hadeler KP. Deterministic models for the eradication of poliomyelitis: Vaccination with the inactivated (IPV) and attenuated (OPV) polio virus vaccine. Mathematical Biosciences, 1995; 127(2):149-166.
28. Elveback LR, Ackerman E, Gatewood L, Fox JP. Stochastic two-agent epidemic simulation models for a community of families. American Journal of Epidemiology, 1971; 93(4):267-280.
29. Fine PE, Carneiro IA. Transmissibility and persistence of oral polio vaccine viruses: Implications for the global poliomyelitis eradication initiative. American Journal of Epidemiology, 1999; 150(10):1001-1021.
30. Agol VI. Vaccine-derived polioviruses. Biologicals 2006; 34(2):103-108.
31. Anderson RM, May RM. Infectious Diseases of Humans: Dynamics and Control. New York: Oxford University Press, 1991.
32. Lloyd AL. Realistic distributions of infectious periods in epidemic models: Changing patterns of persistence and dynamics. Theoretical Population Biology 2001; 60(1):59-71.
33. Sterman J. Business Dynamics: Systems Thinking and Modeling for a Complex World. Boston, MA: McGraw-Hill, 2001.
34. Alexander LN, Seward JF, Santibanez TA, Pallansch MA, Kew OM, Prevots DR, Strebel PM, Cono J, Wharton M, Orenstein WA, Sutter RW. Vaccine policy changes and epidemiology of poliomyelitis in the United States. Journal of the American Medical Association, 2004; 292(14):1696-1701.
35. Edmunds WJ, Gay NJ, Kretzschmar M, Pebody RG, Wachmann H. The pre-vaccination epidemiology of measles, mumps and rubella in Europe: Implications for modelling studies. Epidemiology and Infection, 2000; 125(3):635-650.
36. Diekmann O, Heesterbeek JA, Metz JA. On the definition and the computation of the basic reproduction ratio R0 in models for infectious diseases in heterogeneous populations. Journal of Mathematical Biology, 1990; 28(4):365-382.
37. Jacquez JA, Simon CP, Koopman J, Sattenspiel L, Perry T. Modeling and analyzing HIV transmission: The effect of contact patterns. Mathematical Biosciences, 1988; 92:119-99.
38. Glasser J, Feng Z, Moylan A, Del Valle S, Castillo-Chavez C. Mixing in age-structured population models of infectious diseases. Mathematical Biosciences, 2012; 235(1):1-7.
39. Towers S, Feng Z. Social contact patterns and control strategies for influenza in the elderly. Mathematical Biosciences., 2012; 240(2):241-249.
40. Patriarca PA, Wright PF, John TJ. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: Review. Reviews of Infectious Diseases, 1991; 13:926-939.
41. Plotkin SA, Vidor E. Poliovirus vaccine-Inactivated. Pp. 605-630 in Plotkin SA, Orenstein WA, Offit PA (eds). Vaccines. 5th ed. Philadelphia: Saunders Elsevier, 2008.
42. Centers for Disease Control and Prevention. Progress toward poliomyelitis eradication-Nigeria, January 2011-September 2012. Morbidity and Mortality Weekly Report, 2012; 61(44):899-904.
43. Dowdle WR, van der Avoort HGAM, de Gourville EM, Delpeyroux F, Deshpande JM, Hovi T, Martín J, Pallansch MA, Kew OM, Wolff C. Containment of polioviruses after eradication: Characterizing risk to improve management. Risk Analysis, 2006; 26(6):1449-1469.
44. Duintjer Tebbens RJ, Pallansch MA, Kew OM, Cáceres VM, Jafari H, Cochi SL, Aylward RB, Thompson KM. Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Analysis, 2006; 26(6):1471-1505.
45. Savilahti E, Klemola T, Carlsson B, Mellander L, Stenvik M, Hovi T. Inadequacy of mucosal IgM antibodies in selective IgA deficiency: Excretion of attenuated polio viruses is prolonged. Journal of Clinical Microbiology, 1988; 8(2):89-94.
46. Böttiger M. Polio immunity to killed vaccine: An 18-year follow-up. Vaccine, 1990; 8(5):443-445.
47. Squarcione S, Germinario C, Iandolo E, Lo Caputo S, Bergamini F, Profeta M, Greco D, Quarto M, Barbuti S. Seroimmunity to poliomyelitis in an Albanian immigrant population. Vaccine, 1992; 10(12):853-856.
48. Más Lago P, Bravo JR, Andrus JK, Comellas MM, Galindo MA, de Quadros CA, Bell E. Lesson from Cuba: Mass campaign administration of trivalent oral poliovirus vaccine and seroprevalence of poliovirus neutralizing antibodies. Bulletin of the World Health Organization, 1994; 72(2):221-225
49. Pirez MC, Olivera I, Diabarboure H, Montano A, Baranano R, Badia F, Bonnet MC. Seroprevalence of anti-polio antibodies in a population 7 months to 39 years of age in Uruguay: Implications for future polio vaccination strategies. Vaccine, 2009; 27(20):2689-2694.
50. Prevots DR, Sutter RW, Strebel PM, Weibel RE, Cochi SL. Completeness of reporting for paralytic poliomyelitis, United States, 1980 through 1991. Archives of Pediatrics and Adolescent Medicine, 1994; 148:479-185.
51. Koopman J. Modeling infection transmission. Annual Reviews of Public Health, 2004; 25:303-326.
52. Cáceres VM, Sutter RW. Sabin monovalent oral polio vaccines: Review of past experiences and their potential use after polio eradication. Clinical Infectious Diseases, 2001; 33(4):531-541.
53. Fine PEM, Carneiro IAM. Transmissibility and Persistence of Oral Poliovirus Vaccine Viruses: Implications for the Global Poliomyelitis Eradication Initiative. London: Infectious Disease Epidemiology Unit, Department of Infectious and Tropical Diseases, London School of Hygiene, 1998.
54. Patriarca PA, Sutter RW, Oostvogel PM. Outbreaks of paralytic poliomyelitis, 1976-1995. Journal of Infectious Diseases, 1997; 175(Suppl 1):S165-S172.
55. Francis T, Jr., Korns RF, Voight RB, Boisen M, Hemphill FM, Napier JA, Tolchinsky E. An evaluation of the 1954 poliomyelitis vaccine trials. Summary report. American Journal of Public Health, 1955; 45 (Part II, May Supplement):1-51.
56. Forbes C, Fernando N, de la Motte P, Mendis N. A survey to determine the immunity status and antibody creating effect of oral polio vaccine. Journal of Tropical Medicine and Hygiene, 1980; 83(3):109-113.
57. Prevots DR, Ciofi degli Atti ML, Sallabanda A, Diamanti E, Aylward RB, Kakariqqi E, Fiore L, Ylli A, van der Avoort HG, Sutter RW, Tozzi AE, Panei P, Schinaia N, Genovese D, Oblapenko G, Greco D, Wassilak SG. Outbreak of paralytic poliomyelitis in Albania, 1996: High attack rate among adults and apparent interruption of transmission following nationwide mass vaccination. Clinical Infectious Diseases, 1998; 26(2):419-425.
58. World Health Organization Collaborative Study Group on Oral Poliovirus Vaccine. Factors affecting the immunogenicity of oral poliovirus vaccine: A prospective evaluation in Brazil and the Gambia. World Health Organization collaborative study group on oral poliovirus vaccine. Journal of Infectious Diseases, 1995; 171(5):1097-1106.
59. Triki H, Abdallah M, Ben Aissa R, Bouratbine A, Kacem MBA, Bouraoui S, Koubaa C, Zouari S, Mohsni E, Crainic R, Dellagi K. Influence of host related factors on the antibody response to trivalent oral polio vaccine in Tunisian infants. Vaccine, 1997; 15(10):1123-1129.
60. Rahmandad H, Hu K, Duintjer Tebbens RJ, Thompson KM. Development of an individual-based model for polioviruses: Implications of the selection of network type and outcome metrics. Epidemiology and Infection, 2010; 139(6):836-848.
61. UN Population Division. World population prospects population database: The 2010 revision population database. 2012: http://esa.un.org/wpp/unpp/panel_indicators.htm, accessed April 2, 2012.
62. Mossong J, Hens N, Jit M, Beutels P, Auranen K, Mikolajczyk R, Massari M, Salmaso S, Tomba GS, Wallinga J, Heijne J, Sadkowska-Todys M, Rosinska M, Edmunds WJ. Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Medecine, 2008; 5(3):e74
63. Horby P, Pham QT, Hens N, Nguyen TT, Le QM, Dang DT, Nguyen ML, Nguyen TH, Alexander N, Edmunds WJ, Tran ND, Fox A. Social contact patterns in Vietnam and implications for the control of infectious diseases. PLoS One, 2011; 6(2):e16965.
64. Chen RT, Hausinger S, Dajani AS, Hanfling M, Baughman AL, Pallansch MA, Patriarca PA. Seroprevalence of antibody against poliovirus in inner-city preschool children. Journal of the American Medical Association, 1996; 275(21):1639-1645.
65. Offit PA. The Cutter Incident: How America's First Polio Vaccine Led to the Growing Vaccine Crisis. New Haven: Yale University Press, 2005.
66. Oshinsky DM. Polio. An American Story. New York: Oxford University Press; 2005.
67. Nathanson N, Martin JR. The epidemiology of poliomyelitis: Enigmas surrounding its appearance, epidemicity, and disappearance. American Journal of Epidemiology, 1979; 110(6):672-692.
68. Chin TD, Marine WM, Hall EC, Gravelle CR, Speers JF. Poliomyelitis in Des Moines, Iowa, 1959. The influence of Salk vaccination on the epidemic pattern and the spread of the virus in the community. American Journal of Hygiene, 1961; 74:67-94.
69. Marine WM, Chin TD, Gravelle CR. Limitation of fecal and pharyngeal poliovirus excretion in Salk-vaccinated children. A family study during a type 1 poliomyelitis epidemic. American Journal of Hygiene, 1962;76:173-195.
70. Nathanson N. Eradication of poliomyelitis in the United States. Reviews of Infectious Diseases, 1982; 4(5):940-950.
71. Morris L, Witte JJ, Gardner P, Miller G, Henderson DA. Surveillance of poliomyelitis in the United States, 1962-65. Public Health Reports, 1967; 82(5):417-427.
72. Simpson DM, Ezzati-Rice TM, Zell ER. Forty years and four surveys: How does our measuring measure up? American Journal of Preventive Medicine, 2001; 20(Suppl. 4):6-14.
73. National Communicable Disease Center. Recommendation of the Public Health Advisory Committee on Immunization Practices-Poliomyelitis Vaccines. Morbidity and Mortality Weekly Report, 1967; 16(33):278-279.
74. Centers for Disease Control and Prevention. Past immunization schedules, 2012. Available at: http://www.cdc.gov/vaccines/schedules/past.html, accessed August 24, 2012.
75. Zell ER, Dietz V, Stevenson JM, Cochi SL, Bruce RH. Low vaccination levels of US preschool and school-age children: Retrospective assessments of vaccination coverage, 1991-1992. Journal of the American Medical Association, 1994; 271(11):833-839.
76. World Health Organization. WHO/UNICEF estimated coverage time series. WHO and UNICEF, 2012. Available at: http://www.who.int/entity/immunization_monitoring/data/coverage_estimates_series.xls, accessed April 4, 2012.
77. Hatzandrieu EJ, Palmer CS, Halpern MT. A Cost Benefit Analysis of the OPV Vaccine. Atlanta: Batelle; Centers for Disease Control and Prevention, 1994.
78. Hall WJ, Nathanson N, Langmuir AD. The age distribution of poliomyelitis in the United States in 1955. American Journal of Hygiene, 1957; 66(214-34).
79. Oostvogel P, van Wijngaarden J, van der Avoort HG, Mulders MN, Conyn-van Spaendonck MA, Rümke H, van Steenis G, van Loon AM. Poliomyelitis outbreak in an unvaccinated community in the Netherlands, 1992-3. Lancet, 1994; 344(8923): 665-670.
80. Bijkerk H. Surveillance and control of poliomyelitis in the Netherlands. Reviews of Infectious Diseases, 1984; 6(Suppl. 2):S451-S456.
81. von Magnus H, Petersen I. Vaccination with inactivated poliovirus vaccine and oral poliovirus vaccine in Denmark. Reviews of Infectious Diseases, 1984; 6 (Suppl 2):S471-S474.
82. Diamanti E, Ibrahimi B, Tafaj F, Mezini E, Dodbiba A, Dobi V, Catone S, Genovese D, Simeoni P, Fiore L. Surveillance of suspected poliomyelitis in Albania, 1980-1995: Suggestion of increased risk of vaccine associated poliomyelitis. Vaccine 1998; 16(9):940-948.
83. Fiore L, Genovese D, Diamanti E, Catone S, Ridolfi B, Ibrahimi B, Konomi R, van der Avoort HG, Hovi T, Crainic R, Simeoni P, Amato C. Antigenic and molecular characterization of wild type 1 poliovirus causing outbreaks of poliomyelitis in Albania and neighboring countries in 1996. Journal of Clinical Microbiology, 1998; 36(7):1912-1918.
84. State Committee on Statistics of the Repubic of Tajikistan. Multiple Indicator Cluster Survey 2005, Final Report. Dushanbe, Tajikistan: State Committee on Statistics of the Repubic of Tajikistan, 2007.
85. State Committee on Statistics of the Repubic of Tajikistan. Tajikistan Living Standards Measurement Survey 2007. Dushanbe, Tajikistan: State Committee on Statistics of the Repubic of Tajikistan, 2009.
86. UNICEF. Multiple indicator cluster survey, Tajikistan, April 2000.2000. Available at: http://www.childinfo.org/files/tajikistan.pdf, accessed February 11, 2013.
87. World Health Organization. Incidence series.2012. Available at: http://www.who.int/entity/immunization_monitoring/data/incidence_series.xls, accessed April 6, 2012.
88. Measure DHS. Demographic and health surveys, Nigeria 1990, 1999, 2003, and 2008, 2012. Available at: http://measuredhs.com/, accessed August 20, 2012.
89. Measure DHS. Demographic and health surveys, India, 1992-93, 1998-99, 2005-06, 2013. Available at: http://measuredhs.com/, accessed February 11, 2013.
90. Measure DHS. Demographic and health surveys, Haiti, 1994-95, 2000, and 2005-06, 2013. Available at: http://measuredhs.com/, accessed February 11, 2013.
91. World Health Organization and UNICEF. Tajikistan: WHO and UNICEF estimates of immunization coverage: 2011 revision, 2012. Available at: http://www.who.int/immunization_monitoring/data/tjk.pdf, accessed February 11, 2013.
92. Más Lago P. Eradication of poliomyelitis in Cuba: A historical perspective. Bulletin of the World Health Organization, 1999; 77(8):681-687.
93. Rodriguez Cruz R. Cuba: Mass polio vaccination program, 1962-1982. Reviews of Infectious Diseases, 1984; 6(Suppl 2):S408-S412.
94. Más Lago P, Gary HE, Jr., Pérez LS, Cáceres VM, Olivera JB, Puentes RP, Corredor MB, Jímenez P, Pallansch MA, González Cruz R. Poliovirus detection in wastewater and stools following an immunization campaign in Havana, Cuba. International Journal of Epidemiology, 2003; 32:772-777.
95. Más Lago P, Cáceres VM, Galindo MA, Gary HE, Jr., Valcarcel M, Barrios J, Sarmiento L, Avalos I, Bravo JA, Palomera R, Bello M, Sutter RW, Pallansch MA, de Quadros CA. Persistence of vaccine-derived poliovirus following a mass vaccination campaign in Cuba: Implications for stopping polio vaccination after global eradication. International Journal of Epidemiology, 2001; 30:1029-1034.
96. Kew O, Morris-Glasgow V, Landaverde M, Burns C, Shaw J, Garib Z, Andre J, Blackman E, Freeman CJ, Jorba J, Sutter R, Tambini G, Venczel L, Pedreira C, Laender F, Shimizu H, Yoneyama T, Miyamura T, van Der Avoort H, Oberste MS, Kilpatrick D, Cochi S, Pallansch M, de Quadros C. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science, 2002; 296(5566):356-359.
97. Wringe A, Fine PE, Sutter RW, Kew OM. Estimating the extent of vaccine-derived poliovirus infection. PLoS One, 2008; 3(10):e3433.
98. Olive JM, Risi JB, Jr., de Quadros CA. National immunization days: Experience in Latin America. Journal of Infectious Diseases, 1997; 175 (Suppl 1):S189-S193.
99. de Quadros CA, Andrus JK, Olive J-M, Guerra de Macedo C, Henderson DA. Polio eradication from the Western Hemisphere. Annual Reviews of Public Health, 1992; 13:239-252.
100. Estívariz CF, Watkins M, Handoko D, Rusipah R, Deshpande J, Rana BJ, Irawan E, Widhiastuti D, Pallansch MA, Thapa A, Imari S. A large vaccine-derived poliovirus outbreak on Madura Island-Indonesia, 2005. Journal of Infectious Diseases, 2008; 197(3):347-354.
101. Wassilak SGF, Pate MA, Wannemuehler K, Jenks J, Burns C, Chenoweth P, Abanida EA, Adu F, Baba M, Gasasira A, Iber J, Mkanda P, Williams AJ, Shaw J, Pallansch MA, Kew OM. Outbreak of type 2 vaccine-derived poliovirus in Nigeria: Emergence and widespread circulation in an underimmunized population. Journal of Infectious Diseases, 2011; 203(7):898-909.
102. Centers for Disease Control and Prevention. Progress toward poliomyelitis eradication-Nigeria, January 2002-March 2003. Morbidity and Mortality Weekly Report, 2003; 52(24):567-570.
103. Centers for Disease Control and Prevention. Progress toward poliomyelitis eradication-Nigeria, January 2003-March 2004. Morbidity and Mortality Weekly Report, 2004; 53(16):343-346.
104. Nigeria/Africa Masterweb. Nigeria 2006 census figures, 2013. Available at: http://www.nigeriamasterweb.com/Nigeria06CensusFigs.html, accessed February 11, 2013.
105. Centers for Disease Control and Prevention. Progress toward poliomyelitis eradication-Nigeria, January 2004-July 2005. Morbidity and Mortality Weekly Report, 2005; 54(35):873-877.
106. Centers for Disease Control and Prevention. Progress toward poliomyelitis eradication-Nigeria, 2005-2006. Morbidity and Mortality Weekly Report 2007; 56(12):278-281.
107. Centers for Disease Control and Prevention. Progress toward poliomyelitis eradication-Nigeria, January 2007-August 12, 2008. Morbidity and Mortality Weekly Report, 2008; 57(34):942-946.
108. Centers for Disease Control and Prevention. Progress toward poliomyelitis eradication-Nigeria, January 2008 - July, 2009. Morbidity and Mortality Weekly Report, 2009; 58(41):1150-1154.
109. Centers for Disease Control and Prevention. Progress toward poliomyelitis eradication-Nigeria, January 2009-June 2010. Morbidity and Mortality Weekly Report, 2010; 59(26):802-807.
110. Grassly NC, Wenger J, Durrani S, Bahl S, Deshpande JM, Sutter RW, Heymann DL, Aylward RB. Protective efficacy of a monovalent oral type 1 poliovirus vaccine: A case-control study. Lancet, 2007; 369(9570):1356-1362.
111. World Health Organization. Global Polio Eradication Initiative-Cases of wild poliovirus by country and by year 2000-2011, 2012. Available at: http://www.polioeradication.org/Dataandmonitoring/Poliothisweek/Wildpolioviruslist.aspx, accessed May 13, 2012.
112. South East Asia Regional WHO Office. Immunization and vaccine development-Surveillance, 2011. Available at: http://www.searo.who.int/EN/Section1226/Section1635.htm, accessed January 17, 2011.
113. Sutter RW, Kew OM, Cochi SL. Poliovirus vaccine-Live. Pp. 651-705 in Plotkin SA, Orenstein WA (eds). Vaccines. 4th ed. Philadelphia: W.B. Saunders, 2004.
114. Oostvogel P, Rumke H, Conyn-Van Spaendonck MA, van der Avoort HG, Leeuwenburg J, van Loon AM. Poliovirus circulation among schoolchildren during the early phase of the 1992-1993 poliomyelitis outbreak in the Netherlands. Journal of Infectious Diseases, 2001; 184(11):1451-1455.
115. Bernier RH. Some observations on poliomyelitis lameness surveys. Reviews of Infectious Diseases, 1984; 6 (Suppl 2):S371-S375.
116. World Health Organization. Circulating vaccine-derived poliovirus (cVDPV) 2000-2012, 2012. Available at: http://www.polioeradication.org/Dataandmonitoring/Poliothisweek/Circulatingvaccinederivedpoliovirus.aspx, accessed August 22, 2012.
117. Centers for Disease Control and Prevention. Progress toward poliomyelitis eradication-Nigeria, 1996-1998. Morbidity and Mortality Weekly Report, 1999; 48(15):312-316.
118. World Health Organization. Progress towards global poliomyelitis eradication-The approaching extinction of wild poliovirus type 2. Weekly Epidemiological Record, 1999; 74(34):286-288.
119. Rahmandad H, Sterman J. Heterogeneity and network structure in the dynamics of diffusion: Comparing agent-based and differential equation models. Management Science, 2008; 54(5):998-1014.
120. Duintjer Tebbens RJ, Thompson KM, Hunink M, Mazzuchi TM, Lewandowski D, Kurowicka D, Cooke RM. Uncertainty and sensitivity analyses of a dynamic economic evaluation model for vaccination programs. Medical Decision Making, 2008; 28(2):182-200.
121. World Health Organization. Summary of Discussions and Recommendations, 16th Informal Consultation of the Global Polio Laboratory Network, 22-23 September 2010, WHO/HQ. Geneva: World Health Organization, 2010.
122. Jorba J, Campagnoli R, De L, Kew O. Calibration of multiple poliovirus molecular clocks covering an extended evolutionary range. Journal of Virology, 2008; 82(9):4429-4440.
123. Horstmann DM, Paul JR. The incubation period in human poliomyelitis and its implications. Journal of the American Medical Association, 1947; 135(1):11-14.
124. Centers for Disease Control and Prevention. Progress toward poliomyelitis eradication-Angola, Democratic Republic of Congo, Ethiopia, and Nigeria, January 2000-July 2001. Morbidity and Mortality Weekly Report, 2001; 50(38):826-829.
125. Government of India. 2011 census data. Office of the General & Census Commission, Ministry of Home Affairs, Governement of India, 2013. Available at: http://censusindia.gov.in/, accessed February 11, 2013.
126. Centers for Disease Control and Prevention. Progress toward poliomyelitis eradication-India, January 2007-May 2009. Morbidity and Mortality Weekly Report, 2010; 58(26):718-723.
127. World Health Organization. Progress towards poliomyelitis eradication in India, January 2005 to June 2006. Weekly Epidemiological Record, 2006; 81(29):286-291.
128. World Health Organization. Progress towards poliomyelitis eradication in India, January 2007-May 2009. Weekly Epidemiological Record, 2009; 84(28):281-287.